Insomnia - Pipeline Review, H1 2014

  • April 2014
  • -
  • Global Markets Direct
  • -
  • 93 pages

Insomnia - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Insomnia - Pipeline Review, H1 2014’, provides an overview of the Insomnia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Insomnia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Insomnia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Insomnia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Insomnia - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Insomnia Overview 9
Therapeutics Development 10
Pipeline Products for Insomnia - Overview 10
Pipeline Products for Insomnia - Comparative Analysis 11
Insomnia - Therapeutics under Development by Companies 12
Insomnia - Therapeutics under Investigation by Universities/Institutes 15
Insomnia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Insomnia - Products under Development by Companies 20
Insomnia - Products under Investigation by Universities/Institutes 21
Insomnia - Companies Involved in Therapeutics Development 22
Johnson and Johnson 22
Merck and Co., Inc. 23
Novartis AG 24
Actelion Ltd 25
Eisai Co., Ltd. 26
Mitsubishi Tanabe Pharma Corporation 27
Evotec AG 28
IntelGenx Corp. 29
Neurim Pharmaceuticals Ltd 30
Angelini Group 31
Abeille Pharmaceuticals, Inc. 32
Intec Pharma ltd. 33
Grupo Ferrer Internacional, S.A. 34
Somnus Therapeutics, Inc. 35
Intra-Cellular Therapies, Inc. 36
Heptares Therapeutics Ltd. 37
Insomnia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 48
suvorexant - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
melatonin ER - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
piromelatine - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
osemozotan - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
zaleplon DR - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
EVT-201 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
ITI-007 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
zaleplon GR - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
E-2006 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
trazodone hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
flumazenil - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Orexin Receptor Antagonist for Insomnia - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
lorediplon - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
JNJ-42847922 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
AB-1003 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Drug Targeting Orexin 1/2 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
UCM-765 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Drugs to Inhibit AGTR1 Receptor for Insomnia - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
CR-5542 Series - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Dual Orexin Receptor Antagonist for Insomnia - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
eszopiclone - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Insomnia - Recent Pipeline Updates 75
Insomnia - Dormant Projects 83
Insomnia - Discontinued Products 84
Insomnia - Product Development Milestones 85
Featured News and Press Releases 85
Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia 85
May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 85
May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 86
Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 86
Mar 27, 2013: US Appeals Board Upholds Sanofi's Ambien CR Patent In Inter Partes Reexamination 87
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 87
Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 88
Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 89
Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 89
Jul 26, 2012: Sunovion Pharma Receives Six Month US Pediatric Exclusivity For LUNESTA 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables

Number of Products under Development for Insomnia, H1 2014 10
Number of Products under Development for Insomnia - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Insomnia - Pipeline by Johnson and Johnson, H1 2014 22
Insomnia - Pipeline by Merck and Co., Inc., H1 2014 23
Insomnia - Pipeline by Novartis AG, H1 2014 24
Insomnia - Pipeline by Actelion Ltd, H1 2014 25
Insomnia - Pipeline by Eisai Co., Ltd., H1 2014 26
Insomnia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 27
Insomnia - Pipeline by Evotec AG, H1 2014 28
Insomnia - Pipeline by IntelGenx Corp., H1 2014 29
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 30
Insomnia - Pipeline by Angelini Group, H1 2014 31
Insomnia - Pipeline by Abeille Pharmaceuticals, Inc., H1 2014 32
Insomnia - Pipeline by Intec Pharma ltd., H1 2014 33
Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 34
Insomnia - Pipeline by Somnus Therapeutics, Inc., H1 2014 35
Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H1 2014 36
Insomnia - Pipeline by Heptares Therapeutics Ltd., H1 2014 37
Assessment by Monotherapy Products, H1 2014 38
Number of Products by Stage and Target, H1 2014 41
Number of Products by Stage and Mechanism of Action, H1 2014 44
Number of Products by Stage and Route of Administration, H1 2014 46
Number of Products by Stage and Molecule Type, H1 2014 47
Insomnia Therapeutics - Recent Pipeline Updates, H1 2014 75
Insomnia - Dormant Projects, H1 2014 83
Insomnia - Discontinued Products, H1 2014 84

List of Figures

Number of Products under Development for Insomnia, H1 2014 10
Number of Products under Development for Insomnia - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 38
Number of Products by Top 10 Target, H1 2014 39
Number of Products by Stage and Top 10 Target, H1 2014 40
Number of Products by Top 10 Mechanism of Action, H1 2014 42
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 43
Number of Products by Top 10 Route of Administration, H1 2014 45
Number of Products by Stage and Top 10 Route of Administration, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

EpiCast Report: Insomnia - Epidemiology Forecast to 2023

EpiCast Report: Insomnia - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • February 2015
  • by Global Data

EpiCast Report: Insomnia - Epidemiology Forecast to 2023 Summary GlobalData epidemiologists forecast that the total prevalent cases of acute insomnia in the 7MM will increase from 121,799,911 total prevalent ...

Insomnia - Pipeline Review, H2 2014

Insomnia - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • October 2014
  • by Global Markets Direct

Insomnia - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Insomnia - Pipeline Review, H2 2014’, provides an overview of the Insomnia’s therapeutic pipeline. This report provides comprehensive ...

Insomnia Global Clinical Trials Review, H2, 2014

Insomnia Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • July 2014
  • by Global Data

Insomnia Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. ...


Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • April 2015
    70 pages
  • Pathology  

  • United States  

View report >

Medical Industry in the US

  • April 2015
    76 pages
  • Medical  

    Neurological Di...  

  • United States  

    North America  

View report >

Indigestion Drug Industry in the US

  • March 2015
    32 pages
  • Indigestion Dru...  

    Neurological Di...  

    Diabetes Mellit...  

  • United States  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.